To me it's a good example of how the market (shorters, FOMO, panic etc. ) misprices companies over time.
MSB was over $3 barely 2 months ago and here it's less than half that price with 2 solid announcements. Unlike many stocks hard hit by Covid the only negative to MSB over that time has been the possibility that the Capital funding environment is generally more challenging but it's been hit more than many.
Kudos to management for keeping this quiet.
Ann: FDA Clears IND for Remestemcel Use in COVID-19 ARDS Patients, page-28
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.81 |
Change
0.000(0.00%) |
Mkt cap ! $3.222B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1130 | $3.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.53 | 10 | 1 |
View Market Depth
| Last trade - 16.17pm 10/01/2025 (20 minute delay) ? |
| MSB (ASX) Chart |
Day chart unavailable
